Lupin is currently trading at Rs. 1493.50, up by 1.40 points or 0.09% from its previous closing of Rs. 1492.10 on the BSE.
The scrip opened at Rs. 1509.00 and has touched a high and low of Rs. 1509.00 and Rs. 1482.40 respectively. So far 20659 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1911.55 on 09-Feb-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1,529.10 and Rs. 1478.80 respectively. The current market cap of the company is Rs. 67361.46 crore.
The promoters holding in the company stood at 46.74%, while Institutions and Non-Institutions held 41.85% and 11.41% respectively.
Lupin has received final approval for its Desoximetasone Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA) to market a generic version of Taro Pharms North’s Topicort Ointment, 0.05%. The product filing is from Lupin’s Pithampur (Indore) manufacturing facility. Topicort Ointment had US sales of $12.1 million, as per IMS MAT September 2016.
Lupin’s Desoximetasone Ointment USP, 0.05% is the AB rated generic equivalent of Taro Pharms North’s Topicort Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Lupin had earlier on December 6, 2016, received final approval for its Desoximetasone Ointment USP, 0.25% from USFDA to market a generic version of Taro Pharmaceuticals, Inc.’s Topicort Ointment, 0.25% having US sales of $14.4 million, as per IMS MAT September 2016.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |